Abstract library

6 results for "Suylen".
#65 Deletions of 11q21-q25 are associated with atypical lung carcinoids and a poor clinical outcome
Introduction: Lung carcinoids comprise a group of smoking-unrelated neuroendocrine tumors, which can be classified in typical (TC) and atypical (AC) carcinoids. Classification is complex and its accuracy to predict disease outcome is variable. In a previous array comparative genomic hybridization (arrayCGH) study, we showed that the average number of chromosomal alterations (≥ 1Mb) was significantly higher in ACs than in TCs (512 v. 226 per tumor) and that the most common region of chromosome loss was 11q21-q25 (Neuroendocrinology 2009;90:136-137).
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MSc Dorian RA Swarts
#212 Reduced MEN1 Gene Expression in Pulmonary Carcinoids Is Associated With Metastatic Disease
Introduction: Lung carcinoids are neuroendocrine tumors that can be classified as typical (TC) or atypical (AC) carcinoids. Previously, MEN-1 mutations and associated LOH of 11q13 have been implied in tumorigenesis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MSc Dorian R.A. Swarts
#462 Genome-Wide Expression Profiling Reveals Downregulation of OTP and CD44 and Upregulation of RET as Indicators of Poor Prognosis in Lung Carcinoids
Introduction: Lung carcinoids comprise a heterogeneous group of neuroendocrine tumors. Only few parameters have been identified that correlated with poor disease outcome, including 11q22-q25 deletions. New biomarkers are required to further improve diagnosis and prediction of prognosis.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MSc Dorian Swarts
#653 Interobserver Variability of Pulmonary Carcinoids
Introduction: Lung carcinoids are neuroendocrine tumors histopathologically classified into typical (TC; no necrosis, <2 mitoses/2 mm2) and atypical (AC; necrosis or 2-10 mitoses/2 mm2). Identification of mitoses may be hampered by the presence of apoptotic cells, and reported prediction of prognosis based on histopathology varies, especially for ACs.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MSc Dorian Swarts
#1184 A National Pathology Registration Analysis of Applied Terminology in Pulmonary Neuroendocrine Tumors/Carcinomas: Is the WHO 2004 Classification in Line with Clinical Practice?
Introduction: Nomenclature of the WHO 2004 should be used for pulmonary neuro-endocrine tumors (NET) and carcinomas (NEC) classification.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Jules Derks
Keywords: NET, Diagnosis
#1778 Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter?
Introduction: Metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare disease and the most effective chemotherapy regimen is debated, i.e. small cell lung carcinoma (SCLC) or non-small cell lung carcinoma (NSCLC) chemotherapy.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Jules Derks
Keywords: lcnec, chemotherapy, nec, lung